Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Ultragenyx Pharmaceutical Inc. - Common Stock (NQ:RARE)

22.72 +0.89 (+4.08%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	2,130,122
Open	21.56
Bid (Size)	22.00 (100)
Ask (Size)	22.71 (100)
Prev. Close	21.83
Today's Range	21.31 - 22.87
52wk Range	18.41 - 45.00
Shares Outstanding	70,814,462
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud Class Action Lawsuit Filed; April 6, 2026, Lead Plaintiff Deadline

Today 18:15 EST

Did you buy RARE common stock between August 3, 2023, and December 26, 2025?

Via TheNewswire.com

Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud Class Action Lawsuit Filed; April 6, 2026, Lead Plaintiff Deadline

Today 18:15 EST

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Performance

YTD	-3.7%	-3.7%
1 Month	-2.9%	-2.9%
3 Month	-30.7%	-30.7%
6 Month	-22.4%	-22.4%
1 Year	-46.7%	-46.7%

More News

Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit: Investors Face April 6, 2026, Deadline

February 21, 2026

Via TheNewswire.com

Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit: Investors Face April 6, 2026, Deadline

February 21, 2026

Via NewMediaWire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

February 20, 2026

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm

February 20, 2026

From Schall Law

Via GlobeNewswire

NASDAQ: RARE: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc.

February 19, 2026

Via TheNewswire.com

NASDAQ: RARE: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc.

February 19, 2026

Via NewMediaWire

RARE INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026

February 19, 2026

From Faruqi & Faruqi LLP

Via GlobeNewswire

Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE

February 18, 2026

From SkyMedia, LLC

Via GlobeNewswire

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RARE

February 18, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

Stockholders Who Lost Money Investing in Ultragenyx Pharmaceutical Inc. Should Contact Robbins LLP for Information About Recovering Their Losses from RARE

February 18, 2026

From Robbins LLP

Via GlobeNewswire

CLASS ACTION ALERTS: Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ultragenyx and Mereo BioPharma and Encourages Investors to Contact the Firm

February 17, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

February 17, 2026

From Kahn Swick & Foti, LLC

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines – RARE

February 17, 2026

From Pomerantz LLP

Via GlobeNewswire

RARE Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges RARE Investors With Losses to Contact the Firm

February 17, 2026

Via NewMediaWire

RARE Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges RARE Investors With Losses to Contact the Firm

February 17, 2026

Via TheNewswire.com

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm

February 17, 2026

From Schall Law

Via GlobeNewswire

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RARE

February 15, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

Ultragenyx Pharmaceutical Inc. (RARE) Investors: April 6, 2026 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP

February 15, 2026

Via NewMediaWire

Ultragenyx Pharmaceutical Inc. (RARE) Investors: April 6, 2026 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP

February 15, 2026

Via TheNewswire.com

RARE CLASS ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026

February 15, 2026

From Faruqi & Faruqi LLP

Via GlobeNewswire

RARE Investor Alert: Contact Kessler Topaz Meltzer & Check, LLP About the Securities Fraud Class Action Lawsuit Filed Against Ultragenyx Pharmaceutical Inc. (RARE)

February 14, 2026

Via NewMediaWire

RARE Investor Alert: Contact Kessler Topaz Meltzer & Check, LLP About the Securities Fraud Class Action Lawsuit Filed Against Ultragenyx Pharmaceutical Inc. (RARE)

February 14, 2026

Via TheNewswire.com

INVESTOR ALERT: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

February 13, 2026

From Robbins Geller Rudman & Dowd LLP

Via Business Wire

Frequently Asked Questions

Is Ultragenyx Pharmaceutical Inc. - Common Stock publicly traded?

Yes, Ultragenyx Pharmaceutical Inc. - Common Stock is publicly traded.

What exchange does Ultragenyx Pharmaceutical Inc. - Common Stock trade on?

Ultragenyx Pharmaceutical Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Ultragenyx Pharmaceutical Inc. - Common Stock?

The ticker symbol for Ultragenyx Pharmaceutical Inc. - Common Stock is RARE on the Nasdaq Stock Market

What is the current price of Ultragenyx Pharmaceutical Inc. - Common Stock?

The current price of Ultragenyx Pharmaceutical Inc. - Common Stock is 22.72

When was Ultragenyx Pharmaceutical Inc. - Common Stock last traded?

The last trade of Ultragenyx Pharmaceutical Inc. - Common Stock was at 02/20/26 04:00 PM ET

What is the market capitalization of Ultragenyx Pharmaceutical Inc. - Common Stock?

The market capitalization of Ultragenyx Pharmaceutical Inc. - Common Stock is 1.61B

How many shares of Ultragenyx Pharmaceutical Inc. - Common Stock are outstanding?

Ultragenyx Pharmaceutical Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.